NVIDIA and Two Other Stocks That May Be Undervalued
The US stock market has been volatile in recent times, plummeting by 13% in the last week but still posting a 13% increase over the past year. Identifying undervalued stocks can be crucial for investors looking for opportunities, especially when earnings are forecast to grow by 18% annually.
Simply Wall St's screener tool has identified several undervalued US stocks based on cash flows. One of them is NVIDIA (NVDA), a data center scale AI infrastructure company with a market cap of $5.43 trillion, serving the United States, Taiwan, China, Hong Kong, Europe, and other international markets.
NVIDIA's revenue comes from two main segments: Graphics, generating $27.56 billion, and Compute & Networking, contributing $275.41 billion. The company is estimated to be undervalued based on discounted cash flow analysis with a fair value estimate of $302.83. Its stock trades over 20% below this future cash flow valuation, indicating potential relative value compared to peers and industry standards.
Another undervalued stock is Insulet (PODD), which develops, manufactures, and sells insulin delivery systems for individuals with insulin-dependent diabetes both in the United States and internationally. The company's revenue segment is focused on drug delivery systems, generating approximately $3.05 billion. Insulet is significantly undervalued based on its future cash flow value of $241.73.